Mechanisms of N‑acetylcysteine in reducing monocrotaline‑induced pulmonary hypertension in rats: Inhibiting the expression of Nox1 in pulmonary vascular smooth muscle cells

Yu,Wencheng; Ji,Weina; Mi,Liyun; Lin,Chen

doi:10.3892/mmr.2017.7326

Mechanisms of N‑acetylcysteine in reducing monocrotaline‑induced pulmonary hypertension in rats: Inhibiting the expression of Nox1 in pulmonary vascular smooth muscle cells

Authors:
- Wencheng Yu
- Weina Ji
- Liyun Mi
- Chen Lin
View Affiliations

Affiliations: Department of Respiratory Diseases, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China, Department of Respiratory Diseases, Shenli Oilfield Central Hospital, Dongying, Liaoning 257064, P.R. China
Published online on: August 22, 2017 https://doi.org/10.3892/mmr.2017.7326
Pages: 6148-6155

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the impact of N‑acetylcysteine (NAC) on the expression of reduced nicotinamide adenine dinucleotide phosphate oxidase 1 (Nox1), and the proliferation and apoptosis of pulmonary artery smooth muscle cells (PASMCs) in rats exhibiting monocrotaline (MCT)‑induced pulmonary hypertension, and to investigate the possible mechanisms and treatment roles of NAC in pulmonary vascular remodeling (PVR). A total of 18 Wistar rats were randomly divided into three groups: The control (C) group; the MCT (M) group; and the NAC (N) group. The right ventricular hypertrophy index (RVHI) and other indicators were recorded 6 weeks subsequently. Groups C and M were divided into two subgroups: Groups C1 and M1 (control); and group C2 and M2 group (treated with ML171). Group N was not sub‑divided. PASMCs were isolated, and the vascular remodeling and Nox1 positioning were observed. The expression of Nox mRNA in each group, and the proliferation, apoptosis, and superoxide dismutase (SOD) activity of PASMCs, prior to and following the ML171 treatment, were measured. NAC was able to decrease RVHI and other indicators (P<0.001). The mRNA expression of Nox1 and Nox4 in group M was significantly increased compared with group C (P<0.05), and NAC was able to significantly decrease the expression of these two factors in lung tissue (P<0.001). MCT‑PASMCs exhibited differences in Nox1 mRNA expression (P<0.001), and the total SOD activity was Nox1‑dependently increased (r=0.949; P<0.001). NAC was able to decrease Nox1‑derived reactive oxygen species in PASMCs, thereby improving PVR. Nox1 was able to increase SOD activity, thereby demonstrating its positive effect on the proliferation of MCT‑PASMCs.

View Figures

View References

1	Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Noordegraaf A Vonk, Beghetti M, et al: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 37:67–119. 2016. View Article : Google Scholar : PubMed/NCBI
2	Qiao S, Fan K, Iwashita T, Ichihara M, Yoshino M and Takahashi M: The involvement of reactive oxygen species derived from NADPH oxidase-1 activation on the constitutive tyrosine auto-phosphorylation of RET proteins. Free Radic Res. 48:427–434. 2014. View Article : Google Scholar : PubMed/NCBI
3	Schermuly RT, Ghofrani HA, Wilkins MR and Grimminger F: Mechanisms of disease: Pulmonary arterial hypertension. Nat Rev Cardiol. 8:443–455. 2011. View Article : Google Scholar : PubMed/NCBI
4	Freund-Michel V, Guibert C, Dubois M, Courtois A, Marthan R, Savineau JP and Muller B: Reactive oxygen species as therapeutic targets in pulmonary hypertension. Ther Adv Respir Dis. 7:175–200. 2013. View Article : Google Scholar : PubMed/NCBI
5	Veit F, Pak O, Egemnazarov B, Roth M, Kosanovic D, Seimetz M, Sommer N, Ghofrani HA, Seeger W, Grimminger F, et al: Function of NADPH oxidase 1 in pulmonary arterial smooth muscle cells after monocrotaline-induced pulmonary vascular remodeling. Antioxid Redox Signal. 19:2213–2231. 2013. View Article : Google Scholar : PubMed/NCBI
6	Ismail S, Sturrock A, Wu P, Cahill B, Norman K, Huecksteadt T, Sanders K, Kennedy T and Hoidal J: NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: The role of autocrine production of transforming growth factor-{beta}1 and insulin-like growth factor binding protein-3. Am J Physiol Lung Cell Mol Physiol. 296:L489–L499. 2009. View Article : Google Scholar : PubMed/NCBI
7	Wassmann S, Wassmann K and Nickenig G: Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension. 44:381–386. 2004. View Article : Google Scholar : PubMed/NCBI
8	Millea PJ: N-acetylcysteine: Multiple clinical applications. Am Fam Physician. 80:265–269. 2009.PubMed/NCBI
9	Kelly GS: Clinical applications of N-acetylcysteine. Altern Med Rev. 3:114–127. 1998.PubMed/NCBI
10	Santus P, Corsico A, Solidoro P, Braido F, Di Marco F and Scichilone N: Oxidative stress and respiratory system: Pharmacological and clinical reappraisal of N-acetylcysteine. COPD. 11:705–717. 2014. View Article : Google Scholar : PubMed/NCBI
11	Chaumais MC, Ranchoux B, Montani D, Dorfmüller P, Tu L, Lecerf F, Raymond N, Guignabert C, Price L, Simonneau G, et al: N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. Respir Res. 15:652014. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Veit F, Pak O, Brandes RP and Weissmann N: Hypoxia-dependent reactive oxygen species signaling in the pulmonary circulation: Focus on ion channels. Antioxid Redox Signal. 22:537–552. 2015. View Article : Google Scholar : PubMed/NCBI
14	Ahmad M, Kelly MR, Zhao X, Kandhi S and Wolin MS: Roles for Nox4 in the contractile response of bovine pulmonary arteries to hypoxia. Am J Physiol Heart Circ Physiol. 298:H1879–H1888. 2010. View Article : Google Scholar : PubMed/NCBI
15	Seta F, Rahmani M, Turner PV and Funk CD: Pulmonary oxidative stress is increased in cyclooxygenase-2 knockdown mice with mild pulmonary hypertension induced by monocrotaline. PLoS One. 6:e234392011. View Article : Google Scholar : PubMed/NCBI
16	Briones AM and Touyz RM: Oxidative stress and hypertension: Current concepts. Curr Hypertens Rep. 12:135–142. 2010. View Article : Google Scholar : PubMed/NCBI
17	Guzik TJ, Sadowski J, Guzik B, Jopek A, Kapelak B, Przybylowski P, Wierzbicki K, Korbut R, Harrison DG and Channon KM: Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol. 26:333–339. 2006. View Article : Google Scholar : PubMed/NCBI
18	Cheng G and Lambeth JD: NOXO1, regulation of lipid binding, localization, and activation of Nox1 by the Phox homology (PX) domain. J Biol Chem. 279:4737–4742. 2004. View Article : Google Scholar : PubMed/NCBI
19	Helmcke I, Heumüller S, Tikkanen R, Schröder K and Brandes RP: Identification of structural elements in Nox1 and Nox4 controlling localization and activity. Antioxid Redox Signal. 11:1279–1287. 2009. View Article : Google Scholar : PubMed/NCBI
20	Diebold I, Petry A, Hess J and Görlach A: The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1. Mol Biol Cell. 21:2087–2096. 2010. View Article : Google Scholar : PubMed/NCBI
21	Judkins CP, Diep H, Broughton BR, Mast AE, Hooker EU, Miller AA, Selemidis S, Dusting GJ, Sobey CG and Drummond GR: Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/-mice. Am J Physiol Heart Circ Physiol. 298:H24–H32. 2010. View Article : Google Scholar : PubMed/NCBI
22	Yin W and Voit EO: Function and design of the Nox1 system in vascular smooth muscle cells. BMC Syst Biol. 7:202013. View Article : Google Scholar : PubMed/NCBI
23	Valdivia A, Pérez-Alvarez S, Aroca-Aguilar JD, Ikuta I and Jordán J: Superoxide dismutases: A physiopharmacological update. J Physiol Biochem. 65:195–208. 2009. View Article : Google Scholar : PubMed/NCBI
24	Jaulmes A, Sansilvestri-Morel P, Rolland-Valognes G, Bernhardt F, Gaertner R, Lockhart BP, Cordi A, Wierzbicki M, Rupin A and Verbeuren TJ: Nox4 mediates the expression of plasminogen activator inhibitor-1 via p38 MAPK pathway in cultured human endothelial cells. Thromb Res. 124:439–446. 2009. View Article : Google Scholar : PubMed/NCBI
25	Anrather J, Racchumi G and Iadecola C: NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J Biol Chem. 281:5657–5667. 2006. View Article : Google Scholar : PubMed/NCBI
26	Schröder E and Eaton P: Hydrogen peroxide as an endogenous mediator and exogenous tool in cardiovascular research: Issues and considerations. Curr Opin Pharmacol. 8:153–159. 2008. View Article : Google Scholar : PubMed/NCBI